

# Joint NDAC/DODAC Advisory Committee Meeting March 24, 2005

## Bibliography

- TAB 1** Valencia, E.C. and F.A. Kerdel, "Topical Glucocorticoids," in Freedberg, I.M., A.Z Eisen, K. Wolff, K.F. Austen, L.A. Goldsmith, and S.I. Katz, eds., "Fitzpatrick's Dermatology in General Medicine, Volume II," p. 2325, 2003.
- TAB 5** Munro, D.D. and D.C. Clift, "Pituitary adrenal function after prolonged use of topical corticosteroids," *British Journal of Dermatology*, 88:381-385, 1973.
- TAB 6** Munro, D.D., "The effect of percutaneously absorbed steroids on hypothalamic –pituitary-adrenal function after intensive use in in-patients" *British Journal of Dermatology* 94:67-76:1976
- TAB 7** Cooper, M.S. and P.M. Stewart, "Corticosteroid Insufficiency In Acutely Ill Patients," *New England Journal of Medicine*, :727-734, 2003.
- TAB 8** Hanley, J.A., and A. Lippman-Hand, "If Nothing Goes Wrong, Is Everything All Right? Interpreting Zero Numerators," *Journal of American Medical Association*, 249:1743-1745, 1983.
- TAB 9** Ellison ,J.A., L. Patel, D.W. Ray, and P.E. Clayton, "Hypothalamic-Pituitary-Adrenal Function and Glucocorticoid Sensitivity in Atopic Dermatitis," *Pediatrics* 105:794-799, 2000.
- TAB 10** Seth, A. and A. Aggarwal, "Monitoring Adverse Reactions to Steroid Therapy in Children," *Indian Pediatrics* 41:349-357, 2004.
- TAB 11** Dorin, R.I., C.R. Qualls, and L.M. Crape, "Diagnosis of Adrenal Insufficiency," *Annals of Internal Medicine* 139:194-206, 2003.
- TAB 12** Table: Relative Glucocorticoid And Mineralocorticoid Potency Of Natural Corticosteroids And Some Synthetic Analogs In Clinical Use, from: Berne, R.M. and M.N. Levy (eds.), "Physiology," The C.V. Mosby Company, St. Louis, p. 1046, 1983.
- TAB 13** Table: Relative Potencies and Equivalent Doses of Representative Corticosteroids, from: Hardman, J.G., A.G. Gilman, and L.E. Limbird (eds.), *Goodman and Gilman's The Pharmacological Basis of Therapeutics*, 9th ed., McGraw-Hill, New York, p. 1466, 1996.
- TAB 14A** Abma, E.M., R. Blanken, and L.J. DeHeide, "Cushing's syndrome caused by topical steroid therapy for psoriasis," PubMed ID: 12164372, [www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov)
- TAB 14B** Cook, L.J., R.K. Freinkel, C. Zugerman, D.L. Levin, and R. Radtke, "Iatrogenic hyperadrenocorticism during topical steroid therapy: assessment of systemic effects by metabolic criteria," PubMed ID: 7047591, [www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov)

**TAB 14C**

Weber, S.L., "Cushing's syndrome attributable to topical use of lotrisone," PubMed ID: 15251475, [www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov)

**TAB 15** Picado, C. and M. Luengo, "Corticosteroid-Induced Bone Loss. Prevention and Management," *Drug Safety* 15:347-359, 1996.